Drug Trial Radar · NCT07933848
A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Nov 17, 2026
Primary completion
May 21, 2028
Study completion May 27, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to understand how the body processes the study medicine, called prifetrastat, in people with renal impairment compared to healthy people with normal kidney function. Renal impairment means that a person has worse kidney function than normal. The study will also look at the safety and tolerability of prifetrastat in people with renal impairment compared to healthy people with normal kidney function. This study is seeking participants who: * Have moderate or severe renal impairment or * Healthy people with normal kidney function All participants in this study will receive a single dose of prifetrastat. The study medicine will be given by mouth at the study clinic. We will compare experiences of people with renal impairment and healthy people with normal kidney function. Participants will take part in this study for about 2 months. During this time, they will stay at the study clinic for 8 to 16 days.
Conditions
- Renal Impairment
- Healthy Adults
Interventions
PrifetrastatDrug
Prifetrastat administered by mouth as a single dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PrifetrastatTime frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose
- Maximum Observed Plasma Concentration (Cmax) of PrifetrastatTime frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Floridian Clinical Research
Miami Lakes, Florida
Genesis Clinical Research, LLC
Tampa, Florida
Nucleus Network Minneapolis
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.